Compare KRUS & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRUS | RLMD |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.4M | 461.9M |
| IPO Year | 2019 | 2012 |
| Metric | KRUS | RLMD |
|---|---|---|
| Price | $31.53 | $3.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $65.75 | $10.75 |
| AVG Volume (30 Days) | 197.1K | ★ 1.4M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.75 | 45.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $282,763,000.00 | $13,070.00 |
| Revenue This Year | $16.95 | N/A |
| Revenue Next Year | $18.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 18.88 | ★ 154.83 |
| 52 Week Low | $33.97 | $2.15 |
| 52 Week High | $80.84 | $8.00 |
| Indicator | KRUS | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 24.58 | 39.10 |
| Support Level | N/A | $3.13 |
| Resistance Level | $59.30 | $3.55 |
| Average True Range (ATR) | 1.67 | 0.21 |
| MACD | -0.56 | 0.03 |
| Stochastic Oscillator | 0.16 | 39.57 |
Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.